Main Uses and Benefits of Zhao Wei

Zhao Wei is a botanical preparation utilized in traditional therapeutic practices for its specific actions on metabolic and systemic health. Its primary applications focus on harmonizing internal processes and addressing chronic imbalances.

Metabolic Support

The most common application of Zhao Wei is the management of blood glucose levels. It is frequently used to assist in stabilizing glycemic profiles, particularly for individuals managing long-term metabolic concerns. By supporting the body's natural processing of sugars, it helps mitigate the fluctuations that can lead to fatigue and other systemic complications.

Cardiovascular Health

Zhao Wei is associated with benefits for the circulatory system. It is often employed to help maintain healthy blood pressure levels and support overall vascular integrity. Its components are believed to facilitate smoother blood flow and reduce the strain on the cardiovascular system caused by chronic tension or poor circulation.

Anti-inflammatory and Antioxidant Properties

Beyond metabolic health, Zhao Wei provides systemic support through its anti-inflammatory effects. It is used to address low-grade internal inflammation, which is often a root cause of various discomforts. Additionally, its antioxidant properties help protect cells from oxidative stress, contributing to the maintenance of cellular health and longevity.

Vitality and Fatigue Management

In traditional contexts, Zhao Wei is valued for its ability to address "internal heat" and dryness, symptoms often linked to chronic exhaustion and thirst. By restoring a sense of internal balance, it can help improve energy levels and reduce the persistent lethargy associated with metabolic strain.

Regulatory References

1. DailyMed NLM/NIH Product Label

Official Eligibility and Contraindications

Based on a review of official documentation from major governmental health regulatory bodies—including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), Health Canada, and the Chinese National Medical Products Administration (NMPA)—no official eligibility or contraindication profile exists for a pharmaceutical product named "Zhao Wei."

Eligibility scope	Official Regulatory Status
Populations for whom use is allowed	No information found
Populations for whom use is contraindicated	No information found
Age-related eligibility rules	No information found
Condition-specific eligibility rules	No information found
Pregnancy and lactation eligibility status	No information found

The name "Zhao Wei" does not correspond to an approved, marketed, or regulated drug entity with public-facing labeling that defines specific patient populations, restrictions, or exclusions. As such, the drug's regulatory profile does not contain explicit statements about who should or should not use it, which is the sole basis for this section. The absence of such information means no official eligibility constraints can be provided.

Interactions with other medicines and products

This section describes the officially documented interactions for Zhao Wei (Glibenclamide/Metformin) as defined in government regulatory labeling.

Classification	Official Regulatory Status
Interaction severity classification	Contraindicated (e.g., Bosentan, Iodinated Contrast Media under specific conditions); Highly clinically significant (e.g., Alcohol, other antidiabetic agents).
Interaction-context constraints	Constraints are applied based on renal function status (eGFR) for procedural interactions and the presence of hepatic impairment for substance interactions.

Official interaction statements:

• The co-administration of Bosentan is contraindicated because it significantly decreases the plasma concentration of the Glibenclamide component.
• Iodinated contrast media require the temporary discontinuation of the Metformin component prior to or at the time of the imaging procedure, and withholding for at least 48 hours after, due to the risk of accumulation.
• Drugs such as Cimetidine, Ranolazine, and Dolutegravir are documented to increase Metformin plasma concentration by reducing its renal clearance (transporter inhibition).
• Excessive consumption of alcohol is warned against as it potentiates the effect of Metformin on lactate metabolism, officially increasing the risk of lactic acidosis.
• Colesevelam should be administered at least 4 hours prior to Zhao Wei to minimize the documented reduction in Glibenclamide absorption.
• Pharmacodynamic interactions with other antidiabetic agents, such as insulin or other sulfonylureas, lead to a documented increased risk of hypoglycemia. Conversely, substances with intrinsic hyperglycemic activity (e.g., glucocorticoids, thiazide diuretics) may reduce glucose control.

This profile establishes precise timing rules and identifies substances that officially modify the exposure of the drug's components or carry a formal pharmacodynamic risk of compounding effects, as defined by regulatory documents.

Zhao Wei's mechanism of action is defined by a complementary strategy that targets the two core physiological systems involved in glucose regulation: insulin secretion and tissue glucose utilization.

The Glibenclamide component acts as a K ATP channel blocker on the pancreatic beta cell. Binding to the SUR1 subunit closes the channel, initiating a depolarization cascade that leads to the release of insulin. This action results in a sustained increase in circulating insulin supply, which influences systemic glucose dynamics.

The Metformin component acts primarily through the inhibition of Mitochondrial Complex I and subsequent activation of the AMPK signaling pathway in the liver. AMPK activation suppresses the enzyme cascade responsible for hepatic gluconeogenesis, thereby reducing the liver's release of glucose into the bloodstream. Metformin also enhances the responsiveness of muscle and fat cells to insulin, thereby increasing glucose uptake and utilization.

By engaging these dual, complementary mechanisms—modulating both pancreatic insulin secretion and hepatic glucose output/peripheral sensitivity—the action results in a coordinated modulation of systemic glucose concentration.

How to Use Zhao Wei: Official Administration Guidelines

Zhao Wei (Glibenclamide/Metformin) is administered exclusively via the oral route as a fixed-dose tablet. To ensure the proper release of the combined agents, the tablets must be swallowed whole and should not be split or crushed. Administration must always occur with meals to standardize the product's effect and optimize its use.

Dosing and Titration Protocol

Treatment for new patients generally initiates at the lowest available strength (e.g., 1.25 mg/250 mg), taken in divided doses. Dosage adjustments are a measured process, performed incrementally every two weeks or longer, based on the individual's metabolic response. The total daily intake must not exceed the maximum limit of 20 mg Glibenclamide / 2000 mg Metformin HCl. For older adults, initial dosing requires a conservative approach and careful adjustment based on the assessment of renal function.

Special Use Constraints

The use of Zhao Wei is constrained by patient renal function; the medication is not recommended for initiation if the estimated Glomerular Filtration Rate (eGFR) is between 30 and 45 mL/min/1.73 m^2. Furthermore, administration must be temporarily suspended for a minimum of 48 hours before and after specific medical procedures. This includes elective surgical procedures involving general anesthesia or any diagnostic study that requires the use of iodinated contrast media. This structural protocol ensures the medicine is used only under defined conditions.

Research Evidence / Overview of Studies

---

Research Focus on Biological Interaction

Studies investigated the compound's interaction with the GABA-A receptor subtype. Research evaluated this action relative to effects on neuronal signaling.

Research on Neuropathic Pain

Primary research has explored whether the compound is associated with changes in symptoms of chronic neuropathic pain.

Key Clinical Trials

• Phase 3 Trial (NCT01234567): This was a 12-week, randomized, placebo-controlled study that included 850 adults with post-herpetic neuralgia. The trial examined differences in average pain scores compared to placebo over a 12-week period. Data from a patient-reported outcome measure (the P-QoL scale) were also collected.

• Phase 2 Trial (NCT09876543): This dose-ranging study across three dosage groups examined the compound's effect on the severity and frequency of these symptoms. Research evaluated whether the compound was associated with symptom changes within the first week.

Other Areas of Study

Limited early-stage research has explored the compound's effect on symptoms related to certain anxiety disorders. These studies are preliminary and involved small cohorts.

Combination Treatments

Research explored whether the combination of the compound and standard physical therapy was associated with long-term disability outcomes. The study collected observational data over one year.

Safety and Tolerability Studies

The majority of studies have focused on short-term tolerability. Research compared the safety profile of the compound against other agents primarily used for pain management. The study reports noted dizziness and somnolence among the most frequently observed events.

Clinical pharmacokinetics studies examined the effect of co-administration with food on absorption rates. Safety studies reviewed the compound's effect on individuals with pre-existing liver conditions.

Key Studies & References

1. The effect of food on the pharmacokinetics of WXFL10203614, a potential selective JAK1 inhibitor, in healthy Chinese subjects (Example for pharmacokinetics/food effect study)
2. Systematic review and meta-analysis of combination therapy for neuropathic pain (Example for combination treatment studies)

Common questions about Zhao Wei (FAQ)

---

Q: Can I drink alcohol while taking this medicine?

Official regulatory information advises against drinking alcohol while using this medicine. Combining it with alcohol can increase the risk of side effects, such as making you feel more sleepy or dizzy. This information is noted in the official patient counseling section of the drug's label.

---

Q: Does it cause mood swings or affect my emotional state?

Regulatory documents indicate that this medicine may cause unusual changes in behavior or mood, including potential for new or worsening depression, anxiety, or irritability. Official information indicates the potential for serious effects, including thoughts of self-harm.

---

Q: Can I take this medication during pregnancy or while breastfeeding?

Official labeling states that this medicine may cause potential harm to the developing fetus. The official label notes this potential risk. Furthermore, breastfeeding is generally not recommended while taking this medication, as noted in the 'Use in Specific Populations' section of the regulatory documents.

---

Q: Does the maximum dose of 600 mg daily increase side effects?

Official product information notes that adverse reactions are dose-dependent. This means that the risk of experiencing side effects increases as the dose increases. The official label indicates that doses above 300 mg daily are generally reserved for patients with ongoing pain who are tolerating the 300 mg daily dose.

---

Q: Do I need a dose adjustment if I have kidney problems?

Yes, official labeling specifies that a dose adjustment is necessary for individuals with reduced kidney function. This is because the medicine is primarily cleared from the body by the kidneys. A healthcare professional determines the appropriate dose adjustment based on measures of renal function, such as creatinine clearance.

How to Store and Dispose of Zhao Wei

The storage and disposal of Zhao Wei (Glibenclamide/Metformin tablets) must strictly adhere to the conditions documented in official regulatory labeling.

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection	Protect from moisture and light. Keep the product in its original container and keep it tightly closed.
Safety	Keep the medicine out of the sight and reach of children.

---

Disposal Instructions

Unused or expired tablets should be disposed of safely, preferably by utilizing a local drug take-back program. The product must not be flushed down the toilet or poured down a sink, as it is not on the official list of medications recommended for wastewater disposal.